Replies to post #99909 on Biotech Values

[DewDiligence]

Did ITMN give any specific guidance or were there otherwise any inferences one could draw to determine if Roche is still strongly committed to ITMN's 2nd gen HCV PI that has yet to enter the clinic?

One analyst asked the above question and the answer was, “No comment.” No guidance as to when the unnamed compound might begin phase-1.